Avestar Capital LLC Buys 447 Shares of AstraZeneca PLC (NASDAQ:AZN)

Avestar Capital LLC lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,965 shares of the company’s stock after purchasing an additional 447 shares during the quarter. Avestar Capital LLC’s holdings in AstraZeneca were worth $1,010,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Stratos Wealth Advisors LLC lifted its stake in AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after purchasing an additional 133 shares during the last quarter. Bruce G. Allen Investments LLC raised its holdings in shares of AstraZeneca by 19.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock worth $67,000 after buying an additional 138 shares in the last quarter. Carnegie Investment Counsel lifted its position in shares of AstraZeneca by 0.8% during the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock worth $1,347,000 after buying an additional 138 shares during the last quarter. Crumly & Associates Inc. boosted its stake in AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock valued at $518,000 after buying an additional 143 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its position in AstraZeneca by 40.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after acquiring an additional 146 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $66.36 on Wednesday. The firm has a market cap of $205.76 billion, a PE ratio of 31.75, a price-to-earnings-growth ratio of 1.22 and a beta of 0.47. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The firm’s fifty day moving average is $72.94 and its 200-day moving average is $77.65. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.87 earnings per share. Sell-side analysts predict that AstraZeneca PLC will post 4.1 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on AZN. TD Cowen raised their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.